Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
dc.contributor.author | Khanna, Dinesh | en_US |
dc.contributor.author | Tseng, Chi‐hong | en_US |
dc.contributor.author | Farmani, Niloofar | en_US |
dc.contributor.author | Steen, Virginia | en_US |
dc.contributor.author | Furst, Daniel E. | en_US |
dc.contributor.author | Clements, Philip J. | en_US |
dc.contributor.author | Roth, Michael D. | en_US |
dc.contributor.author | Goldin, Jonathan | en_US |
dc.contributor.author | Elashoff, Robert | en_US |
dc.contributor.author | Seibold, James R. | en_US |
dc.contributor.author | Saggar, Rajeev | en_US |
dc.contributor.author | Tashkin, Donald P. | en_US |
dc.date.accessioned | 2011-11-10T15:31:55Z | |
dc.date.available | 2012-12-03T21:17:29Z | en_US |
dc.date.issued | 2011-10 | en_US |
dc.identifier.citation | Khanna, Dinesh; Tseng, Chi‐hong ; Farmani, Niloofar; Steen, Virginia; Furst, Daniel E.; Clements, Philip J.; Roth, Michael D.; Goldin, Jonathan; Elashoff, Robert; Seibold, James R.; Saggar, Rajeev; Tashkin, Donald P. (2011). "Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group." Arthritis & Rheumatism 63(10): 3078-3085. <http://hdl.handle.net/2027.42/86843> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/86843 | |
dc.description.abstract | Objective Patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) are thought to have the greatest decline in lung function (forced vital capacity [FVC] % predicted) in the early years after disease onset. The aim of this study was to assess the natural history of the decline in FVC % predicted in patients receiving placebo in the Scleroderma Lung Study and to evaluate possible factors for cohort enrichment in future therapeutic trials. Methods Patients randomized to receive placebo (n = 79) were divided into 3 groups based on the duration of SSc (0–2 years, 2–4 years, and >4 years). Descriptive statistics and a mixed‐effects model were used to analyze the rate of decline in the FVC % predicted over a 1‐year period. Additional analyses stratified according to the severity of fibrosis on high‐resolution computed tomography (HRCT) were performed, and interactions between disease severity and disease duration were explored. Results The mean ± SD decline in the unadjusted FVC % predicted during the 1‐year period was 4.2 ± 12.8%. At baseline, 28.5%, 43.0%, and 28.5% of patients were in the groups with disease durations of 0–2 years, 2–4 years, and >4 years, respectively. The rate of decline in the FVC % predicted was not significantly different across the 3 disease groups ( P = 0.85). When stratified by baseline fibrosis on HRCT, the rate of decline in the FVC % predicted was statistically significantly greater in the group with severe fibrosis (mean annualized decline in the FVC % predicted 7.2% versus 2.7% in the groups with no or moderate fibrosis; P = 0.008). The decline observed in the group with severe fibrosis was most pronounced in those with a relatively short disease duration (0–2 years; annualized decline 7.0%). Conclusion Among patients with SSc‐ILD in the Scleroderma Lung Study, the rates of progression of lung disease were similar irrespective of disease duration. The baseline HRCT fibrosis score is a predictor of a future decline in the FVC % predicted in the absence of effective treatment. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Scleroderma Program, 24 Frank Lloyd Wright Drive, SPC 5753, Ann Arbor, MI 48106 | en_US |
dc.contributor.affiliationother | University of California, Los Angeles | en_US |
dc.contributor.affiliationother | Olive View–UCLA Medical Center, Sylmar, California | en_US |
dc.contributor.affiliationother | Georgetown University, Washington, DC | en_US |
dc.contributor.affiliationother | University of Connecticut, Farmington | en_US |
dc.identifier.pmid | 21618205 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/86843/1/30467_ftp.pdf | |
dc.identifier.doi | 10.1002/art.30467 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.identifier.citedreference | Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis, 1972‐2002. Ann Rheum Dis 2007; 66: 940 – 4. | en_US |
dc.identifier.citedreference | Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283 – 9. | en_US |
dc.identifier.citedreference | Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598 – 602. | en_US |
dc.identifier.citedreference | Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248 – 54. | en_US |
dc.identifier.citedreference | Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66. | en_US |
dc.identifier.citedreference | Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007; 56: 1676 – 84. | en_US |
dc.identifier.citedreference | Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592 – 600. | en_US |
dc.identifier.citedreference | White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947 – 54. | en_US |
dc.identifier.citedreference | Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751 – 8. | en_US |
dc.identifier.citedreference | Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, et al, for the Scleroderma Lung Study Group. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial—results from the Scleroderma Lung Study. Rheumatology (Oxford) 2009; 48: 1537 – 40. | en_US |
dc.identifier.citedreference | MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single‐breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720 – 35. | en_US |
dc.identifier.citedreference | Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511 – 22. | en_US |
dc.identifier.citedreference | Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma‐interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high‐resolution CT scan than placebo: findings from the Scleroderma Lung Study. Chest 2009; 136: 1333 – 40. | en_US |
dc.identifier.citedreference | Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, et al. High‐resolution CT scan findings in patients with symptomatic scleroderma‐related interstitial lung disease. Chest 2008; 134: 358 – 67. | en_US |
dc.identifier.citedreference | Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin‐section CT obtained at 10‐mm increments versus limited three‐level thin‐section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977 – 83. | en_US |
dc.identifier.citedreference | Schettino IA, Ab'Saber AM, Vollmer R, Saldiva PH, Carvalho CR, Kairalla RA, et al. Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index. Pathol Res Pract 2002; 198: 347 – 54. | en_US |
dc.identifier.citedreference | Antoniou KM, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008; 20: 686 – 91. | en_US |
dc.identifier.citedreference | Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al, and the Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91 – 8. | en_US |
dc.identifier.citedreference | Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, et al. Systemic sclerosis‐associated interstitial lung disease: proposed recommendations for future clinical trials. Clin Exp Rheumatol 2010; 28: S55 – 62. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.